Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-28
2006-03-28
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C514S438000, C546S312000, C548S205000, C549S077000
Reexamination Certificate
active
07019019
ABSTRACT:
The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.
REFERENCES:
patent: 5492895 (1996-02-01), Vlasuk et al.
patent: 5534498 (1996-07-01), Brunck et al.
patent: 5658939 (1997-08-01), Abelman et al.
patent: 5681844 (1997-10-01), Abelman et al.
patent: 5696231 (1997-12-01), Abelman et al.
patent: 5703208 (1997-12-01), Semple et al.
patent: 5714499 (1998-02-01), Semple et al.
patent: 5731413 (1998-03-01), Webb et al.
patent: 5739112 (1998-04-01), Brunck et al.
patent: 5770600 (1998-06-01), Abelman et al.
patent: 5883077 (1999-03-01), Brunck et al.
patent: 5886146 (1999-03-01), Vlasuk et al.
patent: 5972616 (1999-10-01), O'Brien et al.
patent: 6025472 (2000-02-01), Abelman et al.
patent: 6034215 (2000-03-01), Semple et al.
patent: 6335155 (2002-01-01), Wells et al.
patent: 6392010 (2002-05-01), Salvino et al.
patent: 6506754 (2003-01-01), Siev et al.
patent: 6586405 (2003-07-01), Semple et al.
patent: 6838074 (2005-01-01), Carpenter, Jr.
patent: WO 99/42120 (1999-08-01), None
patent: WO 00/05245 (2000-02-01), None
patent: WO 00/05245 (2000-02-01), None
patent: WO 00/26211 (2000-05-01), None
patent: WO 00/53232 (2000-09-01), None
patent: WO 00/53232 (2000-09-01), None
patent: WO 01/29056 (2001-04-01), None
patent: WO 01/57194 (2001-08-01), None
patent: WO 01/57194 (2001-08-01), None
patent: WO 01/97794 (2001-12-01), None
patent: WO 01/97794 (2001-12-01), None
patent: WO 02/08392 (2002-01-01), None
patent: WO 02/08392 (2002-01-01), None
Coligan, J. E. et al. (eds.) Current Protocols in Protein Science, John Wiley and Sons, 1997.
Doonan, S. (ed.) Protein Purification Protocols, Humana Press, 1966.
Gennaro, A.R. (ed.) Remington's Pharmaceutical Sciences, Mack Publishing Co., 1985, at p. 1449.
Bock, P.E. et al., “Isolation of human blood coagulation alpha-factor Xa by soybean trypsin inhibitor-sepharose chromatography and its active-site titration with fluorescein mono-p-guanidinobenzoate”Arch. Biochem. Biophys., vol. 273, pp. 375-388 (1989).
Boring, et al., “Cancer Statistics, 1993”CA Cancer J. Clin., vol. 43, p. 7 (1993).
Brooks et al., “Use of the 10-day-old chick embryo model for studying angiogenesis”Methods Mol. Biol., vol. 129, pp. 257-269 (1999).
Enyedy et al., “Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase”J. Med. Chem., 44:1349-1355 (2001).
Graham, J. E. et al., “Theoretical studies applied to drug design: ab initio electronic distribution of bioisosteres”J. Mol. Structure(Theochem), vol. 343, pp. 105-109 (1995).
Hunter, T., “Cooperation between oncogenes”Cell, vol. 64, No. 2; pp. 249-270 (1991).
Land, et al., “Cellular oncogenes and multistep carcinogenesis”Science, vol. 222, p. 771 (1983).
Lin et al., “Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease”J. Biol. Chem., vol. 274, No. 26; pp. 18237-18242 (1999).
Lin et al., “Molecular cloning of cdna for matriptase, a matrix-degrading serine protease with trypsin-like activity”J. Biol. Chem., vol. 274, No. 26; pp. 18231-18236 (1999).
Liotta, et al., “Metastatic potential correlates with enzymatic degradation of basement membrane collagen”Nature, vol. 284, pp. 67-68 (1980).
Lipinski, “Bioisosterism in drug design”Annual Reports in Medicinal Chemistry, vol. 21, Section VI, Chapter 27, pp. 283-291 (1986).
McDonnell and Matrisian, “Stromelysin in tumor progression and metastasis,”Cancer Metastasis Rev., vol. 9, No. 4; pp. 305-319 (1990).
Matrisian and Bowden, “Stromelysin/transin and tumor progression,”Seminars in Cancer Biology, vol. 1, pp. 107-115 (1990).
Mignatti, et al., “Biology and biochemistry of proteinases in tumor invasion,”Physiol. Rev., vol. 73, No. 1; pp. 161-195 (1993).
Ossowski, L., “In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase,”J. Cell. Biol., vol. 107, No. 6; pp. 2437-2445 (1988).
Ruley, H.E., “Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture,”Nature, vol. 304, No. 5927; pp. 602-606 (1983).
Takeuchi, et al., “Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates,”J. Biol. Chem., vol. 275, No. 34; pp. 26333-26342 (2000).
Tamura, et al. “Novel benzo-fused lactam scaffolds as factor Xa inhibitors”Bioorg. Med. Chem. Lett., vol. 9, No. 17; pp. 2573-2578 (1999).
Yun, S.H., “Application of bioisosterism to new drug design,”Hwahak Sekye, vol. 33, No. 8; pp. 576-579 (1993) [Korean].
Zhao, G. and H. Yang, “Bioisosteric replacement and development of lead compounds in drug designs”Huaxue Tongbao, No. 6, pp. 34-38 (1995) [Chinese].
Alfaro-Lopez L. Josue
Duncan David F.
Komandla Mallareddy
Levy Odile Esther
Moreno Ofir
Dendreon Corporation
Lambkin Deborah C.
Townsend and Townsend / and Crew LLP
LandOfFree
Matriptase inhibitors and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Matriptase inhibitors and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matriptase inhibitors and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528610